C4 Therapeutics Expands Roche Partnership with $20M Upfront, $1B+ Milestones for DACs

summarizeSummary

C4 Therapeutics announced an expanded collaboration with Roche for degrader-antibody conjugates (DACs), including a $20 million upfront payment and potential for over $1 billion in milestones and royalties.

check_boxKey Events

• Expanded Collaboration with Roche

  C4 Therapeutics entered into a new Research Collaboration and License Agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to discover, develop, and commercialize degrader-antibody conjugates (DACs) for two initial undisclosed oncology targets, with an option for a third.

• Significant Upfront Payment

  Roche will make an upfront cash payment of $20.0 million to C4 Therapeutics.

• Substantial Milestone Potential

  C4 Therapeutics is eligible to receive over $1.0 billion in aggregate development, regulatory, and commercial milestone payments, plus tiered royalties on net sales, across the collaboration.

• Validation of TORPEDO Platform

  The agreement leverages C4T's proprietary TORPEDO platform for designing degrader payload candidates, with Roche responsible for antibody selection, conjugation, and all development, regulatory, manufacturing, and commercialization costs.

auto_awesomeAnalysis

This 8-K filing confirms a significant expansion of C4 Therapeutics' long-standing partnership with Roche, providing substantial non-dilutive funding and validating C4T's proprietary TORPEDO platform. The $20 million upfront payment represents a material cash injection for a company of this size, and the potential for over $1 billion in future milestones, plus tiered royalties, significantly de-risks the development of degrader-antibody conjugates (DACs) for oncology targets. This collaboration strengthens C4T's financial position and provides a clear path for advancing its pipeline with a major pharmaceutical partner, reducing the need for near-term dilutive financing for these programs.